Upregulation of SOCS3 in the peripheral blood of JAK2 V617F-positive MPN patients is consistent with a previous report [16] and is also expected, given existing information on the JAK–STAT signaling pathway [3]–[5]. Here, JAK2 is linked to myeloproliferative disorder.